Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...

Novo Nordisk’s board of directors is still going through changes. | The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.

The pharma industry has spent much of the last year navigating the Trump administration's tariff threats, but with a seismic Supreme Court ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

McKinney explains how tariff concerns drove last year’s manufacturing surge and why Atradius expects a period of stabilization ahead. He also discusses how companies are weighing the risk of future ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) will push out its February vaccine confab to an undetermined date next month, Bloomberg reported Thursday, citing an unnamed person close ...

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...

After winning an initial U.S. nod in July 2023, Beyfortus has gone on to do gangbusters for Sanofi and AZ, growing total sales 9.5% last year for a total haul of 1.78 billion euros (roughly $2.1 ...